tbuckley/cabot-search huggingface dataset:
Megatal, Crispr/Cas9, and Talen T-Cell Receptor Gene Editing
Authors: Mark J. Osborn, Beau R Webber, Friederike Knipping, Cara-lin Lonetree, Anthony DeFeo, Amber McElroy, Colby Starker, Richard Gabriel, Sarah Merkel, Keli L. Hippen, Daniel Voytas, Christof von Kalle, Manfred Schmidt, Jeffrey S. Miller, Jordan Jarjour, Alexander Astrakhan, Andrew M Scharenberg, Jakub Tolar, Bruce R. Blazar
Journal: Blood (2015)
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Patients (pts) Older Than 50 Years: a Retrospective Single Center Study
Authors: Marie Robin, Raphael Porcher, Lionel Ades, Emmanuel Raffoux, Régis Peffault de Latour, Anna Petropoulou, Nicolas Boissel, Patricia Ribaud, Agnès Devergie, Vanderson Rocha, Pierre Fenaux, Hervé Dombret, Gérard Socié
Journal: Blood (2008)
Oral Administration of PBI-1402 Significantly Reduces Erythropenia and Accelerates Peripheral Blood Recovery in Myeloablated Mice Post Transplantation.
Authors: Marie-Josée Morin, Gorazd Krosl, Mouna Lagraoui, Brigitte Grouix, Christopher Penney, Lyne Gagnon, Denis-Claude Roy
Journal: Blood (2006)
PTU-022 Needleknife Assisted Cannulation in a UK Tertiary Referral Centre – Utilisation and Complications in Standard Practice
Authors: KA Mcwhirter, J McLaughlin, A Makin
Journal: Gut (2016)

<h3>Introduction</h3> Needleknife assisted cannulation has been shown to be effective in ERCPs where standard techniques have failed. Concerns regarding risk of complication, particularly pancreatitis and perforation, have led to it being used only as a last resort. We evaluated the current practice and safety profile in a regional tertiary referral centre. <h3>Methods</h3> We performed a prospective observational study of ERCP outcomes in patients with intact ampullae. Experienced endoscopists with HPB expertise performed all ERCPs, and were asked to follow their standard practice. We used three ampulla classifications; non-prominent, prominent and distorted by tumour. The number of attempts at cannulation was recorded, as were the techniques used. Primary outcome measures were cannulation success and complication rates. <h3>Results</h3> Over a period of 8 months, 222 procedures were performed on patients who had not had previous ERCP. Successful cannulation in this group was achieved in 91.7%. Needleknife assisted cannulation was performed in 37 cases (17%). All needleknife cuts were started at the ampullary orifice. Needleknife use varied between different ampulla types (p = 0.44). Needleknife cannulation was most frequently attempted in ampullae involving tumour (33% attempted) but often unsuccessful (60% failure), compared to non-distorted (16.7% attempted, 22% failure rate). There was a wide range in the number of cannulation attempts made in both the needleknife and non needleknife groups (range 1–25) but there was a significant difference between the number of cannulation attempts in the standard cannulation and needleknife groups (p &lt; 0.001). Despite this, there was no difference in the complication rate between standard cannulation and needleknife groups 5.6% v 7.3% (p = 0.522). <h3>Conclusion</h3> Needleknife assisted cannulation is more likely to be used where the ampulla is involved with tumour and where ERCP is indicated for malignant disease. However, in this context, needleknife assisted cannulation is more likely to fail. Reassuringly despite being used after failed attempts at cannulation using standard techniques, the complication rate for needleknife-assisted cannulation is not statistically different. The likelihood of progression to needleknife use may be predicted by ERCP indication and ampullary characteristics. This may facilitate consideration of an early conversion to needleknife-assisted cannulation, but also early abandonment of procedure for alternative methods (percutaneous or surgical) in these groups. <h3>Disclosure of Interest</h3> None Declared
AB0210 Quality of Life Indexes in Patients with Very Early Rheumatoid Arthritis (VERA): A Two Center Subgroup Analysis from The Adapthera Cohort: Table 1.
Authors: K. Triantafyllias, R. Leiß, A. Lauter, M. De Blasi, M. Hesse, A. Schwarting
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The significance of early diagnosis and early therapy initiation in patients with RA is tremendous. ADAPTHERA is a state wide rheumatology network based in Rhineland-Palatinate, Germany. ADAPTHERA aims to improve RA prognosis and quality of patients` life by reducing the time-to-RA-diagnosis. While there have been a lot of studies regarding quality of life in patients with established RA<sup>1,2</sup>, adequate data concerning very early rheumatoid arthritis (VERA) (disease duration &lt;3 months) are lacking. <h3>Objectives</h3> To study quality of life in VERA patients and to investigate its associations with various RA associated clinical and laboratory parameters. <h3>Methods</h3> In a two center subgroup analysis from the ADAPTHERA cohort, we studied quality of life indexes such as Hannover Functional Ability Questionnaire (HFAQ), Health Assessment Questionnaire (HAQ), EuroQol-5D-3L (EQ-5D-3L), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and World Health Organisation-5 Well Being Index (WHO-5) in patients with VERA. Moreover, we examined the statistical relationship of these indexes with various clinical and laboratory RA associated parameters such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF)-/ cyclic citrullinated peptide antibodies (anti-CCP)-status and Disease Activity Score 28 (DAS28) as well as its components [counts of tender and swollen joints, Visual Analogue Scale (VAS)]. <h3>Results</h3> 74 Patients (50 females, 24 males) with a median age of 62 years (IQR 49, 71) were identified as VERA patients. 36 of them were anti-CCP positive and 34 RF positive. Median scores for HFAQ, HAQ, EQ-5D-3L, FACIT-Fatigue, and WHO-5 were 75.5 (IQR 61, 92.5), 0.75 (IQR 0.26, 1.25), 0.89 (IQR 0.79, 0.89), 40 (IQR 32, 46) and 60 (IQR 32, 76) accordingly. The results of the statistical associations between these scores and RA associated parameters are seen in Table 1. <h3>Conclusions</h3> The quality of life indexes HFAQ, HAQ, EQ-5D-3L and WHO-5 are associated with two or more markers of disease activity in patients with VERA. Therefore, improvement of patients9 quality of life is linked to the achievement of disease remission. In contrast, the FACIT-fatigue index seems to be solely associated with arthritis pain intensity. Thus, improvement of fatigue requires an effective pain management strategy. <h3>References</h3> Gossec L et al., RMD Open. 2015 Apr 2;1(1):e000019. Her M et al., Curr Opin Rheumatol, 2012 May;24(3):327–34. <h3>Disclosure of Interest</h3> None declared
Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.
Authors: Sabina Chiaretti, Xiaochun Li, Robert Gentleman, Cheng Li, Antonella Vitale, Marco Mancini, Cristina Mecucci, Robin Foa, Jerome Ritz
Journal: Blood (2004)
AB0292 Low Serum Albumin, Glucocorticoid and Leflunomide Use Were Associated with Permanent Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis
Authors: S. Chaiamnuay, P. Limpawittayakul
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Methotrexate (MTX) is the first line therapy for treatment of rheumatoid arthritis (RA) because of high efficacy and saved cost. MTX has toxicities such as GI irritation, hepatitis, pneumonitis and cytopenia. However, MTX toxicities usually mild and does not lead to discontinuation. MTX toxicities have never been studied in Thailand, which prevalence of hepatitis B infection was high (26%). <h3>Objectives</h3> To examine the prevalence and reasons of discontinuation of MTX in RA and to determine factors, especially previous hepatitis B infection, associated with MTX discontinuation. <h3>Methods</h3> All 197 RA patients according to American College of Rheumatology (ACR) 1987 and/or ACR and European league of Rheumatology 2010 between 2000 and 2015 were studied. Anti-hepatitis B core antibody (anti-HBcAb), hepatitis B surface antigen (HBsAg), chest film were revealed prior to start methotrexate. Patients with positive HBsAg were excluded. Measurements of aspartate aminotransferase (AST), alanine aminotransferase (ALT), complete blood counts, signs and symptoms of methotrexate toxicities were recorded. Potential risk factors for toxicity were recorded. Univariable and multivariated analyses were performed to identify associated factors for permanently discontinuation of MTX. <h3>Results</h3> One hundred and ninety-seven RA patients were followed for 2142 person-years of MTX exposure. MTX was discontinued permanently in 47 patients (24%). Reasons for discontinuation were as followed: leucopenia 12 patients (26%), anemia8 patients (17%), thrombocytopenia3 patients (6%), pneumoitis11 patients (23%), GI irritation8 patients (17%), mild hepatitis (AST40–80 IU/mL) 8 patients (17%), severe hepatitis (AST&gt;80 IU/mL) 8 patients (17%), mucositis 5 patients (10%), alopecia1 patient (2%). Mean time (standard deviation) to discontinuation was 522 (26.9) days. Multivariate logistic regression analyses found that serum albumin level less than 3.5 mg/dL, leflunomide use of more than 10 mg/d and prednisolone use of more than 10 mg per day were significantly associated with methotrexate discontinuation (odd ratio and 95% confidence interval of 15.33 (1.37–171.23), 5.33 (1.40–20.27)2.97 (1.14–7.77), respectively). Previous resolved hepatitis B infection defined as patients with positive anti-HBcAb was not associated with methotrexate discontinuation. <h3>Conclusions</h3> MTX discontinuation occurred in almost one-fourth of patients. Low serum albumin, glucocorticoid and leflunomide use were associated with permanent discontinuation of methotrexate in patients with rheumatoid arthritis. <h3>References</h3> Chongsrisawat V et al., Tropical Medicine and International Health. doi: 10.1111/j.1365-3156.2006.01709.x Volume 11 no 10 pp 1496–1502 October 2006 Tropical Medicine and International Health. volume 11 no 10 pp 1496–1502 October 2006. <h3>Disclosure of Interest</h3> None declared
Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide
Authors: Eiju Negoro, Chantana Polprasert, Tomas Radivoyevitch, Vera Adema, Naoko Hosono, Hideki Makishima, Bartlomiej Przychodzen, Mikkael A. Sekeres, Valeria Santini, Kathy McGaw, Alan F. List, Francesc Sole, Jaroslaw P. Maciejewski
Journal: Blood (2015)
The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34+/CD38−/Lin− Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α
Authors: Harald Herrmann, Irina Sadovnik, Sabine Cerny-Reiterer, Katharina Blatt, Viviane Ghanim, Susanne Herndlhofer, Gregor Hoermann, Thomas Rülicke, Michael Willmann, Gerlinde Mitterbauer-Hohendanner, Matthias Mayerhofer, Wolfgang R. Sperr, Peter Valent
Journal: Blood (2011)
The Multiple Myeloma SET Domain (MMSET) Protein Is a Histone H3 and H4 Methyltransferase with Properties of a Transcriptional Co-Repressor.
Authors: Jotin Marango, Manabu Shimoyama, Boris A. Leibovitch, Ming Ming Zhou, Yolanda Martinez, Andres Sirulnik, Marta Chesi, P. Leif Bergsagel, Jonathan D. Licht
Journal: Blood (2005)
FRI0390 Use of Muscle Biopsies for The Diagnosis of Systemic Vasculitis in A Rheumatology Service:
Authors: S. Rodríguez-Muguruza, J. Sanint, X. Saenz-Sarda, A. Prior-Español, Y. García-Mira, S. Holgado, L. Mateo, J. Cañellas, M. Martinez-Morillo, X. Tena, I. Casas, J.L. Mate, A. Olive
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic vasculitis (SV) comprises a group of diseases characterized by inflammation of vessels in various organs. Histopathological confirmation is required for the diagnosis. The biopsy of an involved organ is invasive and carries the risk of complications. By contrast, gastrocnemius muscle biopsy is simple and minimally invasive technique that may be performed by a rheumatologist. <h3>Objectives</h3> To evaluate the diagnostic use of muscle biopsies for the diagnosis of SV. <h3>Methods</h3> Retrospective study 1984 - 2015. Center: tertiary academic hospital, referral area 850.000 inhabitants. We analyzed the database of all muscular biopsies performed at our hospital. We selected patients undergoing a muscular biopsy for possible diagnosis of SV and we analyzed the clinical, laboratory, neurophysiological and pathologic data. Biopsies were classified as positive (presence of necrotizing vasculitis or non necrotizing vasculitis seen by optical microscopy) or negative for vasculitis. Muscular biopsy was performed in all cases at the medial gastrocnemius muscle ("open" and unilateral) by a rheumatologist. The diagnosis of SV was based on clinical, serological and histological data. <h3>Results</h3> A total of 619 muscular biopsies were performed, 55 were indicated with suspicion of SV, 52.7% female, 47.3% male, median age 64.4 years (DS 15.22); 47 (85.4%) were positive (sensitivity of 85%) and 8 (14.6%) were negative. The positive biopsy group showed more electromiographic alterations (p=0.01) than negative group. Furthermore, the positive biopsy group showed more frequently systemic manifestations such as: weight loss, myalgia, paresthesias, purpura and testicular pain but these differences were not statistically significant. No complications were encountered in the procedure. <h3>Conclusions</h3> Our results suggest that muscle biopsy is a simple, clinically useful, safe and minimally invasive procedure for the diagnosis of SV with high sensitivity. No significant differences were observed in clinical or analytical features between patients with positive or negative biopsy, except in electromyography patients with positive biopsy had more a frequent pathological pattern. <h3>Disclosure of Interest</h3> None declared
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia: Comparison of Outcomes Among HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors and HLA-Mismatched Family Donors
Authors: Sijian Yu, Jing Sun, Zhiping Fan, Yu Zhang, Qianli Jiang, Fen Huang, Min Dai, Hongsheng Zhou, Dan Xu, Yongqiang Wei, Li Xuan, Qifa Liu
Journal: Blood (2014)
Cognitive Subtypes of Schizophrenia Characterized by Differential Brain Volumetric Reductions and Cognitive Decline
Authors: Danielle Weinberg, Rhoshel Lenroot, Isabella Jacomb, Katherine Allen, Jason Bruggemann, Ruth Wells, Ryan Balzan, Dennis Liu, Cherrie Galletly, Stanley V. Catts, Cynthia Shannon Weickert, Thomas W. Weickert
Journal: JAMA Psychiatry (2016)

Cognitively distinct subgroups of schizophrenia have been defined based on premorbid and current IQ, but little is known about the neuroanatomical differences among these cognitive subgroups.To confirm previous findings related to IQ-based subgroups of patients with schizophrenia in an independent sample and extend those findings to determine the extent to which brain volumetric differences correspond to the IQ-based subgroups.A total of 183 participants were assessed at the outpatient settings of Neuroscience Research Australia and Lyell McEwin Hospital from September 22, 2009, to August 1, 2012. Patients were classified using cluster analysis on the basis of current and premorbid IQ differences. Regional magnetic resonance imaging (MRI) brain volumes were compared among the IQ-based subgroups using analysis of covariance with intracranial volume and age as covariates.Wechsler Adult Intelligence Scale, third edition, scores; Wechsler Test of Adult Reading scores; Positive and Negative Syndrome Scale scores; and MRI brain volumes.Ninety-six outpatients (mean [SD] age, 35.7 [8.4] years; age range, 18-51 years; 59 men) with schizophrenia or schizoaffective disorder and 87 healthy controls (mean [SD] age, 31.9 [8.4] years; age range, 20-50 years; 46 men) were studied. Sixty-two patients and 67 healthy controls underwent structural MRI of the brain. Cluster analyses revealed 25 putatively preserved patients (26%), 33 moderately deteriorated patients (34%), 27 severely deteriorated patients (28%), and 11 compromised patients (12%). Negative symptom scores were significantly worse in the severely deteriorated group relative to the putatively preserved group (F2,82 = 13.8, P < .001, effect size [ES] = 1.40). Patient subgroups analyzed revealed significantly reduced inferior parietal volume relative to controls (F3,113 = 9.7, P < .001, ES = 0.85-1.24). The severely deteriorated group had significantly reduced total hippocampal (mean [SEM], 8309.6 [175.0] vs 9024.0 [145.5]; P = .01), lingual gyrus (mean [SEM], 11 996.0 [531.5] vs 13 838.1 [441.9]; P = .05), and superior temporal sulcus (mean [SEM], 4697.8 [192.0] vs 5446.0 [159.6]; P = .05) gray matter volumes relative to the putatively preserved group (ES = 0.91-1.10).Using an independent sample, we obtained proportions in each IQ-based subgroup that were similar to our previous work. Inferior parietal volume reduction was characteristic of schizophrenia relative to controls, and the severely deteriorated IQ group had widespread volumetric reductions. Classifying cognitive heterogeneity in schizophrenia provides a platform to better characterize the neurobiological underpinnings of the illness and its treatment.
Clinically Significant Aberrant HAS1Vb Splicing of the Hyaluronan Synthase 1 Gene (HAS1) Requires a Combination of Mutations and Deletions in Introns 3 and 4 of HAS1 Minigene,
Authors: Jitra Kriangkum, Andrew R Belch, Linda M. Pilarski
Journal: Blood (2011)
High-Dose Therapy/Stem Cell Support (HDT), Including Tandem Transplant, for Primary Refractory Multiple Myeloma (MM): Results from the Spanish Myeloma Group (PETHEMA/GEM) in 49 Patients.
Authors: L. Rosinol, R. Garcia-Sanz, J. J. Lahuerta, M. Hernandez-Garcia, A. Sureda, J. de la Rubia, J. M. Ribera, B. Hernandez-Ruiz, D. Carreras, I. Navarro, J. C. Garcia-Ruiz, S. Gardella, J. Garcia-Larana, J. Diaz-Mediavilla, J. F. San Miguel, J. Blade
Journal: Blood (2005)
A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)
Authors: C. Michel Zwaan, Stefan Söderhäll, Benoit Brethon, Matteo Luciani, Carmelo Rizzari, David Sternberg, Emmanuelle Besse, Catherine Dutreix, Franca Fagioli, Phoenix Ho, Carlo Dufour, Rob Pieters
Journal: Blood (2015)
A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.
Authors: Heather Renfroe, Edmund K. Waller, Mike Arnold, Louette Vaughn, R. Donald Harvey, Ellie Hamilton, Sagar Lonial, H. Jean Khoury, Jonathan L. Kaufman, Mary Jo Lechowicz
Journal: Blood (2009)
Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry
Authors: Louise de Swart, Alex Smith, Pierre Fenaux, Guillermo Sanz, Eva Hellstrom-Lindberg, Argyris Symeonidis, Jaroslav Cermak, Ulrich Germing, Reinhard Stauder, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, Mette Skov Holm, Krzysztof Madry, Sophie Park, Odile Beyne-Rauzy, Jackie Droste, David Bowen, Theo de Witte
Journal: Blood (2012)
A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib),
Authors: Alice C Fan, Liwen Xu, Kunju J Sridhar, Mai Tran, Prajna Banerjee, John P. Renschler, Radha Tripuraneni, Francois Wilhelm, Peter L. Greenberg, Dean W. Felsher
Journal: Blood (2011)
PTH-016 Factors Associated with Upper Gastrointestinal Cancer Occurrence After OGD that Did Not Detect Cancer in The West Midlands
Authors: D Cheung, J Rees, T Evans, N Trudgill
Journal: Gut (2016)

<h3>Introduction</h3> Up to 14% of upper gastrointestinal cancer (UGIC) subjects had an OGD that did not diagnose cancer up to 3 years prior to diagnosis. The rate of and associated risk factors for post-OGD upper gastrointestinal cancer (POUGIC) in the West Midlands were examined. <h3>Methods</h3> Computerised OGD records from 8 NHS trusts in the West Midlands between 1998 and 2010 were retrieved and submitted to the West Midlands Cancer Intelligence Unit (WMCIU) for UGIC registrations linkage. Subjects undergoing OGD 3 to 36 months before diagnosis were identified as POUGIC and subjects with no OGD 3 to 36 months prior to diagnosis served as controls. The influence of age, gender, indication, endoscopist specialty, trainee involvement, sedation, number of biopsies taken from focal abnormalities, site and histology of UGIC on POUGIC were examined by logistic regression analysis. <h3>Results</h3> 115,113 OGD records were submitted to WMCIU and 3870 UGIC were linked. After exclusions, 2909 UGIC subjects were analysed. There were 275 (9.5%) POUGIC subjects (154 oesophageal cancer (OC) and 121 gastric cancer (GC)). The POUGIC rate ranged from 7.6 to 11.8% between the trusts. Of the POUGIC subjects, 143 (52.0%) had OGD 3 to 12 months and 132 (48.0%) 12 to 36 months prior to UGIC diagnosis. POUGIC subjects were younger (69.6±11.7 yrs) compared with controls (72.0±11.6 yrs) (p = 0.001). There were no association between POUGIC and OC or GC (GC OR 1.15, 95%CI 0.89–1.48, p = 0.289) or subject gender (female 1.14, 0.88–1.48, p = 0.312). Subjects with alarm symptoms (0.33, 0.26–0.43, p &lt; 0.0001) were three times less likely to be associated with POUGIC. POUGIC subjects had less biopsies taken from focal lesions (4.2±2.2) compared with controls (5.4±2.6)(p &lt; 0.0001). There was no association between POUGIC and endoscopist speciality (surgical 1.00, 0.71–1.40, p = 0.998) or nurse endoscopist (0.74, 0.43–1.29, p = 0.291). Trainee involvement was not associated with POUGIC (0.80, 0.60–1.07, p = 0.130). There were also no significant association between POUGIC and sedation (1.30, 0.97–1.76, p = 0.084) or sedation and topical anaesthesia (1.07, 0.76–1.49, p = 0.708), compared with topical anaesthesia alone. POUGIC subjects were more likely to undergo surgery (1.75, 1.33–2.29, p = 0.0001) but not chemotherapy (0.81, 0.62–1.06, p = 0.122) or radiotherapy (1.07, 0.79–1.46, p = 0.667). However, there was no significant survival difference at 1 yr (1.24, 0.97–1.60, p = 0.087) between POUGIC and controls. <h3>Conclusion</h3> The POUGIC rate in the West Midlands was 9.5% between 1998 and 2010 and varied between 7.6 and 11.8% between trusts. POUGIC was associated with younger age, a lack of alarm symptoms and less biopsies from abnormalities. There was no significant survival difference between POUGIC subjects and controls at 1 yr. <h3>Disclosure of Interest</h3> None Declared